Quest Diagnostics Director Robert B. Carter Acquires 10 Shares via Dividend Reinvestment Plan

Transaction Overview

On October 21, 2026, Robert B. Carter, a Director of Quest Diagnostics Inc ($DGX), acquired 10 shares of common stock at a price of $235.93 per share, totaling approximately $2,359.30. The transaction was executed via a broker-administered dividend reinvestment plan (DRIP), recorded under Transaction Code 'L' (small acquisition / deferred reporting) and voluntarily reported early on Form 4.

Insider Holdings Context

Following this transaction, Mr. Carter's direct holdings increased to 3,874 shares of Quest Diagnostics common stock. The transaction represents an incremental addition of roughly 0.26% to his pre-existing direct position.

Significance & Market Impact

• Trading Significance: Low
• Rationale: The transaction represents an automated dividend reinvestment rather than a discretionary open-market buy or sell decision. Given the modest transaction size ($2,359.30), this filing does not signal a shift in executive sentiment or forward-looking company performance.